Catalog No.
DHD82301
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
IGFBP8, IGF-binding protein 8, IBP-8, CTGF, HCS24, CCN family member 2, CCN2, Cellular communication network factor 2, Hypertrophic chondrocyte-specific protein 24, Connective tissue growth factor, Insulin-like growth factor-binding protein 8, IGFBP-8
Concentration
4.35mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P29279
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
FG-3019, CAS: 946415-13-0
Clone ID
Pamrevlumab
[Diabetic nephropathy: emerging treatments], PMID: 24938412
Antibodies to watch in 2020, PMID: 31847708
Antibody-based therapies for idiopathic pulmonary fibrosis, PMID: 32098521
Anti-connective tissue growth factor (CTGF/CCN2) monoclonal antibody attenuates skin fibrosis in mice models of systemic sclerosis, PMID: 28610597
Anti-connective tissue growth factor antibody treatment reduces extracellular matrix production in trabecular meshwork and lamina cribrosa cells, PMID: 24204045
Blocking CTGF/CCN2 reduces established skeletal muscle fibrosis in a rat model of overuse injury, PMID: 32227398
Blocking CTGF/CCN2 reverses neural fibrosis and sensorimotor declines in a rat model of overuse-induced median mononeuropathy, PMID: 32379362
Breathe, breathe in the air: the anti-CCN2 antibody pamrevlumab (FG-3019) completes a successful phase II clinical trial for idiopathic pulmonary fibrosis, PMID: 31811619
Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancer, PMID: 26575166
Connective Tissue Growth Factor Is a Novel Prodepressant, PMID: 29861095
Connective tissue growth factor-specific monoclonal antibody inhibits growth of malignant mesothelioma in an orthotopic mouse model, PMID: 29719620
CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer, PMID: 23836645
CTGF is a therapeutic target for metastatic melanoma, PMID: 23435419
Denervation-induced skeletal muscle fibrosis is mediated by CTGF/CCN2 independently of TGF-β, PMID: 30716392
Effects of CTGF Blockade on Attenuation and Reversal of Radiation-Induced Pulmonary Fibrosis, PMID: 28376190
FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in idiopathic pulmonary fibrosis, PMID: 26965296
FG-3019, a Human Monoclonal Antibody Recognizing Connective Tissue Growth Factor, is Subject to Target-Mediated Drug Disposition, PMID: 27059922
Focal segmental glomerulosclerosis: molecular genetics and targeted therapies, PMID: 26156092
Gemcitabine/nab-paclitaxel with pamrevlumab: a novel drug combination and trial design for the treatment of locally advanced pancreatic cancer, PMID: 32817130
Inhibition of CTGF ameliorates peritoneal fibrosis through suppression of fibroblast and myofibroblast accumulation and angiogenesis, PMID: 28710437
Molecular targets for treatment of kidney fibrosis, PMID: 23179685
Novel agents in the management of pancreatic adenocarcinoma: phase I studies. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011, PMID: 21386633
Novel agents in the treatment of pancreatic adenocarcinoma, PMID: 23474556
Novel therapies for diabetic kidney disease, PMID: 24602462
Onkologie und Versorgung in Fach- und Publikumsmedien: Antikörper Pamrevlumab bei radiogen induzierter Lungenfibrose? L-Carnitin und Omega-3-Fettsäuren zur Verhinderung von Kardiotoxizität durch Anthrazykline? Krebsrisiko bei Nachkommen nach Kinderwunschbehandlung? Tumormarker CA 50 beim Pankreaskarzinom – noch relevant? Immunschwäche nach Krebstherapie?, PMID: 33173255
Pamrevlumab for the treatment of idiopathic pulmonary fibrosis, PMID: 32447983
Pamrevlumab in idiopathic pulmonary fibrosis, PMID: 31575507
Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial, PMID: 31575509
Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria, PMID: 20522536
Quantitative CT analysis using functional imaging is superior in describing disease progression in idiopathic pulmonary fibrosis compared to forced vital capacity, PMID: 30400950
Radiation-induced pulmonary gene expression changes are attenuated by the CTGF antibody Pamrevlumab, PMID: 29347981
Surgical strategies and novel therapies for locally advanced pancreatic cancer, PMID: 28513899
Systematic Review and Meta-analysis of Pirfenidone, Nintedanib, and Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis, PMID: 33054319
Targeting connective tissue growth factor (CTGF) in acute lymphoblastic leukemia preclinical models: anti-CTGF monoclonal antibody attenuates leukemia growth, PMID: 24154679
Treatment of Renal Fibrosis-Turning Challenges into Opportunities, PMID: 28284377
Dong, J., Xiao, J., Li, J., Yu, H., Zhao, Q., Tang, Q., Chen, H., Liu, H., Wu, K., and Lei, J. (2023). Discovery and Design of Novel Cyclic Peptides as Specific Inhibitors Targeting CCN2 and Disrupting CCN2/EGFR Interaction for Kidney Fibrosis Treatment. J Med Chem 66, 8251-8266. PMID: 37279405
For research use only. Not for human or drug use.
